NasdaqGM:BWAY

Stock Analysis Report

Executive Summary

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Brainsway's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.8%

BWAY

1.9%

US Medical Equipment

0.4%

US Market


1 Year Return

n/a

BWAY

15.6%

US Medical Equipment

6.9%

US Market

Return vs Industry: Insufficient data to determine how BWAY performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how BWAY performed against the US Market.


Shareholder returns

BWAYIndustryMarket
7 Day-1.8%1.9%0.4%
30 Day-14.8%-1.7%-1.1%
90 Day-12.0%-0.03%-0.5%
1 Yearn/a16.5%15.6%9.3%6.9%
3 Yearn/a72.1%66.9%45.8%36.4%
5 Yearn/a125.8%100.8%62.9%45.1%

Price Volatility Vs. Market

How volatile is Brainsway's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Brainsway undervalued compared to its fair value and its price relative to the market?

3.06x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate BWAY's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate BWAY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BWAY is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: BWAY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate BWAY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BWAY is good value based on its PB Ratio (3.1x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Brainsway forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

23.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BWAY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BWAY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BWAY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BWAY's revenue (29.6% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: BWAY's revenue (29.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if BWAY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Brainsway performed over the past 5 years?

-11.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BWAY is unprofitable, and losses have increased over the past 5 years at a rate of -11.9% per year.

Accelerating Growth: Unable to compare BWAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BWAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: BWAY has a negative Return on Equity (-31.49%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: BWAY is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BWAY is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Brainsway's financial position?


Financial Position Analysis

Short Term Liabilities: BWAY's short term assets ($33.6M) exceeds its short term liabilities ($7.1M)

Long Term Liabilities: BWAY's short term assets (33.6M) exceeds its long term liabilities (7.8M)


Debt to Equity History and Analysis

Debt Level: BWAY is debt free.

Reducing Debt: BWAY had no debt 5 years ago.


Balance Sheet

Inventory Level: BWAY has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BWAY's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BWAY has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BWAY has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -27.4% each year


Next Steps

Dividend

What is Brainsway's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BWAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BWAY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BWAY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BWAY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BWAY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Brainsway's salary, the management and board of directors tenure and is there insider trading?

4.0yrs

Average management tenure


CEO

David Zacut (66yo)

0.08yrs

Tenure

US$177,000

Compensation

Dr. David Zacut, MD, serves as Interim Chief Executive Officer of Brainsway Ltd. since September 2019. Dr. Zacut founded Brainsway Ltd. in 2006 and has been its Chairman since 2006. Dr. Zacut served as an  ...


Management Age and Tenure

4.0yrs

Average Tenure

48yo

Average Age

Experienced Management: BWAY's management team is considered experienced (4 years average tenure).


Board Age and Tenure

8.1yrs

Average Tenure

61yo

Average Age

Experienced Board: BWAY's board of directors are considered experienced (8.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Avi Posen (52yo)

    Vice President of Global Sales

    • Tenure: 4.2yrs
  • David Zacut (66yo)

    Founder

    • Tenure: 0.08yrs
    • Compensation: US$177.00k
  • Ronen Segal (46yo)

    Chief Technology Officer

    • Tenure: 2.8yrs
    • Compensation: US$281.00k
  • Hadar Levy (45yo)

    CFO & COO

    • Tenure: 5.1yrs
    • Compensation: US$325.00k
  • Avraham Zangen (49yo)

    Co-Founder

    • Tenure: 0.3yrs
    • Compensation: US$75.00k
  • Yiftach Roth (48yo)

    Founder & Chief Scientist

    • Tenure: 13.8yrs
    • Compensation: US$108.00k
  • Aron Tendler

    Chief Medical Officer

    • Tenure: 4yrs
  • Moria Ankri (35yo)

    Vice President Research & Development

    • Tenure: 2.1yrs
    • Compensation: US$169.00k

Board Members

  • Karen Sarid (69yo)

    Director

    • Tenure: 1.8yrs
  • David Zacut (66yo)

    Founder

    • Tenure: 0.08yrs
    • Compensation: US$177.00k
  • Avner Hagai (63yo)

    Founder & Vice-Chairman of the Board

    • Tenure: 12.9yrs
    • Compensation: US$30.00k
  • Avraham Zangen (49yo)

    Co-Founder

    • Tenure: 0.3yrs
    • Compensation: US$75.00k
  • Daniel Azriel (67yo)

    Director

    • Tenure: 12.8yrs
    • Compensation: US$1.41k
  • Gavriel Magen (58yo)

    Director

    • Tenure: 12.8yrs
    • Compensation: US$1.55k
  • Orly Uri (59yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$10.25k
  • Eti Mitrany (49yo)

    Director

    • Tenure: 3.3yrs
  • Mark George

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • David Feifel

    Member of the Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Brainsway Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Brainsway Ltd.
  • Ticker: BWAY
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ₪337.326m
  • Listing Market Cap: ₪95.190m
  • Shares outstanding: 22.24m
  • Website: https://www.brainsway.com

Number of Employees


Location

  • Brainsway Ltd.
  • Bynet Building
  • 3rd Floor
  • Jerusalem
  • 9777518
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BWAYTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSSep 2007
BRSY.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2007
BWAYNasdaqGM (Nasdaq Global Market)SPONSORED ADSUSUSDApr 2019

Biography

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:37
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.